About Syntopix
Syntopix Group plc is a specialised research and development business, focusing on the discovery of topical antimicrobials for healthcare and pharmaceutical applications.
Our vision is to become a world-class Company, providing solutions for dermatological conditions by creating a continuous pipeline of novel antimicrobial products.
The Syntopix strategy has been designed to reduce the risks and costs associated with drug discovery and development. We concentrate on repositioning known compounds, or beneficial combinations of compounds, that have a history of use in humans .
Antimicrobial drug discovery is a tough challenge with healthcare and pharmaceutical businesses recognising the need to access external scientific understanding and advancement in order to fill R&D pipelines. Here at Syntopix we offer diversity in thinking and access to cutting edge science at reduced cost and risk.
Recent News
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126
12/11/2009 07:00
Syntopix focuses development efforts around three specific core compounds
14/04/2009 13:13
EXCLUSIVE EVALUATION AGREEMENT
Syntopix signs an exclusive evaluation agreement with a major consumer healthcare company..